
|Articles|June 1, 2004
Chemo studies mark new era in prostate Ca care
Studies of the effect of chemotherapy in men with metastatic prostatecancer have been enticing and, at the same time, disappointing. While showingPSA response in some cases, these studies have previously failed to demonstrateimproved survival. This is all about to change, and for the better. We areentering an exciting new era in the management of this patient population.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
4
Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS
5






